| Wren Hollingsworth, CNP | |
|
100 Mac Ln, Pierre, SD 57501-3391 | |
| (605) 224-5901 | |
| Not Available |
| Full Name | Wren Hollingsworth |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 6 Years |
| Location | 100 Mac Ln, Pierre, South Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205308095 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | CP001513 (South Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Avera St Mary's Hospital | Pierre, SD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Avera St Marys | 0143134965 | 84 |
News Archive
MorphoSys AG's (FSE: MOR; Prime Standard Segment, TecDAX) partner OncoMed Pharmaceuticals today announced that Proceedings of the National Academy of Sciences of the United States of America (PNAS) has published online data demonstrating the potent anti-cancer activity of OMP-18R5, a HuCAL antibody targeting the Wnt pathway, in multiple preclinical human tumor models. OMP-18R5 is currently in Phase 1 clinical testing.
A previous study of ex-NFL players showed that the damage caused by concussions occurs in the same region of the brain as damage caused by Alzheimer's disease, resulting in increased concern over post-concussion related injuries and trauma of athletes. Philip Schatz Ph.D., professor of psychology, and his associates recently published a study in Neurosurgery that identifies potentially enduring effects of multiple previous concussions on high school students.
The cost of health insurance could hinder President Obama's goal of achieving universal coverage.
Researchers have long known that air pollution can increase the risk of disorders such as obesity, diabetes, and fertility, but they did not know the exact mechanism for how it can lead to these health conditions.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
› Verified 4 days ago
| Entity Name | Avera St Marys |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669457180 PECOS PAC ID: 0143134965 Enrollment ID: O20040225000579 |
News Archive
MorphoSys AG's (FSE: MOR; Prime Standard Segment, TecDAX) partner OncoMed Pharmaceuticals today announced that Proceedings of the National Academy of Sciences of the United States of America (PNAS) has published online data demonstrating the potent anti-cancer activity of OMP-18R5, a HuCAL antibody targeting the Wnt pathway, in multiple preclinical human tumor models. OMP-18R5 is currently in Phase 1 clinical testing.
A previous study of ex-NFL players showed that the damage caused by concussions occurs in the same region of the brain as damage caused by Alzheimer's disease, resulting in increased concern over post-concussion related injuries and trauma of athletes. Philip Schatz Ph.D., professor of psychology, and his associates recently published a study in Neurosurgery that identifies potentially enduring effects of multiple previous concussions on high school students.
The cost of health insurance could hinder President Obama's goal of achieving universal coverage.
Researchers have long known that air pollution can increase the risk of disorders such as obesity, diabetes, and fertility, but they did not know the exact mechanism for how it can lead to these health conditions.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Wren Hollingsworth, CNP 100 Mac Ln, Pierre, SD 57501-3391 Ph: (605) 224-5901 | Wren Hollingsworth, CNP 100 Mac Ln, Pierre, SD 57501-3391 Ph: (605) 224-5901 |
News Archive
MorphoSys AG's (FSE: MOR; Prime Standard Segment, TecDAX) partner OncoMed Pharmaceuticals today announced that Proceedings of the National Academy of Sciences of the United States of America (PNAS) has published online data demonstrating the potent anti-cancer activity of OMP-18R5, a HuCAL antibody targeting the Wnt pathway, in multiple preclinical human tumor models. OMP-18R5 is currently in Phase 1 clinical testing.
A previous study of ex-NFL players showed that the damage caused by concussions occurs in the same region of the brain as damage caused by Alzheimer's disease, resulting in increased concern over post-concussion related injuries and trauma of athletes. Philip Schatz Ph.D., professor of psychology, and his associates recently published a study in Neurosurgery that identifies potentially enduring effects of multiple previous concussions on high school students.
The cost of health insurance could hinder President Obama's goal of achieving universal coverage.
Researchers have long known that air pollution can increase the risk of disorders such as obesity, diabetes, and fertility, but they did not know the exact mechanism for how it can lead to these health conditions.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
› Verified 4 days ago
Danielle Campbell, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 100 Mac Ln, Pierre, SD 57501 Phone: 605-224-5901 | |
Julie Ann Cox, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 100 Mac Ln, Pierre, SD 57501 Phone: 605-224-5901 | |
Ericka Leslie Petersen, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 100 Mac Ln, Pierre, SD 57501 Phone: 605-224-5901 | |
Sarah Jane Speck, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 801 E Sioux Ave, Pierre, SD 57501 Phone: 605-224-3100 | |
Ms. Tami Lynn Hogie-lorenzen, CNP Nurse Practitioner Medicare: May Accept Medicare Assignments Practice Location: 1714 Abbey Road, Pierre, SD 57501 Phone: 605-224-8841 Fax: 605-224-6852 | |
Mrs. Kimberly Haines, CNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 640 E Sioux Ave, Pierre, SD 57501 Phone: 605-945-5560 |